Annual CFO
$1.09 B
-$179.97 M-14.15%
31 December 2023
Summary:
Jazz Pharmaceuticals annual cash flow from operations is currently $1.09 billion, with the most recent change of -$179.97 million (-14.15%) on 31 December 2023. During the last 3 years, it has risen by +$192.36 million (+21.38%). JAZZ annual CFO is now -14.15% below its all-time high of $1.27 billion, reached on 31 December 2022.JAZZ Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$398.75 M
+$67.39 M+20.34%
30 September 2024
Summary:
Jazz Pharmaceuticals quarterly cash flow from operations is currently $398.75 million, with the most recent change of +$67.39 million (+20.34%) on 30 September 2024. Over the past year, it has increased by +$91.55 million (+29.80%). JAZZ quarterly CFO is now -4.60% below its all-time high of $417.99 million, reached on 30 September 2022.JAZZ Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$1.16 B
+$91.55 M+8.53%
30 September 2024
Summary:
Jazz Pharmaceuticals TTM cash flow from operations is currently $1.16 billion, with the most recent change of +$91.55 million (+8.53%) on 30 September 2024. Over the past year, it has dropped by -$101.97 million (-8.05%). JAZZ TTM CFO is now -15.83% below its all-time high of $1.38 billion, reached on 31 March 2023.JAZZ TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
JAZZ Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.2% | +29.8% | -8.1% |
| 3 y3 years | +21.4% | +45.5% | +48.0% |
| 5 y5 years | +36.7% | +18.1% | +28.4% |
JAZZ Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -14.2% | +40.3% | -4.6% | +138.3% | -15.8% | +65.8% |
| 5 y | 5 years | -14.2% | +40.6% | -4.6% | +856.3% | -15.8% | +65.8% |
| alltime | all time | -14.2% | +938.5% | -4.6% | +994.3% | -15.8% | +934.8% |
Jazz Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $398.75 M(+20.3%) | $1.16 B(+8.5%) |
| June 2024 | - | $331.35 M(+24.0%) | $1.07 B(+3.3%) |
| Mar 2024 | - | $267.23 M(+59.7%) | $1.04 B(-4.9%) |
| Dec 2023 | $1.09 B(-14.1%) | $167.34 M(-45.5%) | $1.09 B(-13.8%) |
| Sept 2023 | - | $307.19 M(+3.5%) | $1.27 B(-8.0%) |
| June 2023 | - | $296.76 M(-7.5%) | $1.38 B(-0.5%) |
| Mar 2023 | - | $320.71 M(-6.2%) | $1.38 B(+8.8%) |
| Dec 2022 | $1.27 B(+63.4%) | $341.97 M(-18.2%) | $1.27 B(+14.8%) |
| Sept 2022 | - | $417.99 M(+37.9%) | $1.11 B(+14.9%) |
| June 2022 | - | $303.04 M(+45.0%) | $963.83 M(+37.2%) |
| Mar 2022 | - | $208.98 M(+17.6%) | $702.49 M(-9.8%) |
| Dec 2021 | $778.51 M(-13.5%) | $177.75 M(-35.1%) | $778.51 M(-1.1%) |
| Sept 2021 | - | $274.06 M(+557.3%) | $787.02 M(+2.1%) |
| June 2021 | - | $41.70 M(-85.4%) | $770.85 M(-15.4%) |
| Mar 2021 | - | $285.00 M(+53.0%) | $911.68 M(+1.3%) |
| Dec 2020 | $899.65 M(+15.9%) | $186.27 M(-27.8%) | $899.65 M(+12.3%) |
| Sept 2020 | - | $257.89 M(+41.3%) | $801.17 M(-9.0%) |
| June 2020 | - | $182.52 M(-33.1%) | $880.79 M(+4.0%) |
| Mar 2020 | - | $272.97 M(+210.9%) | $847.12 M(+9.1%) |
| Dec 2019 | $776.40 M(-2.8%) | $87.80 M(-74.0%) | $776.40 M(-14.4%) |
| Sept 2019 | - | $337.50 M(+126.7%) | $906.70 M(+14.7%) |
| June 2019 | - | $148.85 M(-26.4%) | $790.67 M(-5.2%) |
| Mar 2019 | - | $202.25 M(-7.3%) | $833.80 M(+4.4%) |
| Dec 2018 | $798.90 M(+15.3%) | $218.10 M(-1.5%) | $798.90 M(+1.7%) |
| Sept 2018 | - | $221.47 M(+15.4%) | $785.37 M(+4.3%) |
| June 2018 | - | $191.97 M(+14.7%) | $752.79 M(+8.2%) |
| Mar 2018 | - | $167.36 M(-18.2%) | $695.91 M(+0.4%) |
| Dec 2017 | $693.09 M(+17.0%) | $204.56 M(+8.3%) | $693.09 M(+3.6%) |
| Sept 2017 | - | $188.90 M(+39.8%) | $669.22 M(+9.1%) |
| June 2017 | - | $135.09 M(-17.9%) | $613.35 M(+1.3%) |
| Mar 2017 | - | $164.54 M(-8.9%) | $605.28 M(+2.2%) |
| Dec 2016 | $592.39 M(+11.4%) | $180.69 M(+35.8%) | $592.39 M(+11.5%) |
| Sept 2016 | - | $133.03 M(+4.7%) | $531.44 M(-7.3%) |
| June 2016 | - | $127.01 M(-16.2%) | $573.49 M(-2.3%) |
| Mar 2016 | - | $151.65 M(+26.7%) | $587.04 M(+10.4%) |
| Dec 2015 | $531.94 M | $119.74 M(-31.6%) | $531.94 M(-2.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2015 | - | $175.08 M(+24.5%) | $546.46 M(+9.1%) |
| June 2015 | - | $140.57 M(+45.6%) | $501.08 M(+15.1%) |
| Mar 2015 | - | $96.56 M(-28.1%) | $435.44 M(+6.8%) |
| Dec 2014 | $407.61 M(+41.3%) | $134.26 M(+3.5%) | $407.61 M(+15.7%) |
| Sept 2014 | - | $129.70 M(+73.1%) | $352.38 M(-0.3%) |
| June 2014 | - | $74.92 M(+9.0%) | $353.47 M(+23.0%) |
| Mar 2014 | - | $68.72 M(-13.0%) | $287.26 M(-0.4%) |
| Dec 2013 | $288.43 M(+15.5%) | $79.03 M(-39.6%) | $288.43 M(-8.1%) |
| Sept 2013 | - | $130.79 M(+1400.0%) | $313.74 M(+38.2%) |
| June 2013 | - | $8.72 M(-87.5%) | $227.10 M(-23.1%) |
| Mar 2013 | - | $69.89 M(-33.0%) | $295.35 M(+18.3%) |
| Dec 2012 | $249.75 M(+64.7%) | $104.34 M(+136.4%) | $249.75 M(+32.1%) |
| Sept 2012 | - | $44.14 M(-42.6%) | $189.07 M(-1.0%) |
| June 2012 | - | $76.97 M(+216.8%) | $190.98 M(+26.1%) |
| Mar 2012 | - | $24.30 M(-44.4%) | $151.44 M(-0.1%) |
| Dec 2011 | $151.60 M(+157.5%) | $43.66 M(-5.2%) | $151.60 M(+16.0%) |
| Sept 2011 | - | $46.05 M(+23.0%) | $130.73 M(+26.7%) |
| June 2011 | - | $37.44 M(+53.1%) | $103.16 M(+34.3%) |
| Mar 2011 | - | $24.45 M(+7.3%) | $76.82 M(+30.5%) |
| Dec 2010 | $58.87 M(-470.8%) | $22.79 M(+23.3%) | $58.87 M(+55.5%) |
| Sept 2010 | - | $18.49 M(+66.7%) | $37.85 M(+377.8%) |
| June 2010 | - | $11.09 M(+70.6%) | $7.92 M(-287.3%) |
| Mar 2010 | - | $6.50 M(+266.8%) | -$4.23 M(-73.4%) |
| Dec 2009 | -$15.88 M(-87.8%) | $1.77 M(-115.5%) | -$15.88 M(-56.4%) |
| Sept 2009 | - | -$11.44 M(+981.5%) | -$36.44 M(-32.1%) |
| June 2009 | - | -$1.06 M(-79.5%) | -$53.68 M(-44.8%) |
| Mar 2009 | - | -$5.15 M(-72.6%) | -$97.21 M(-25.4%) |
| Dec 2008 | -$130.23 M(+60.6%) | -$18.79 M(-34.5%) | -$130.23 M(-6.6%) |
| Sept 2008 | - | -$28.69 M(-35.7%) | -$139.51 M(+10.6%) |
| June 2008 | - | -$44.59 M(+16.8%) | -$126.19 M(+28.3%) |
| Mar 2008 | - | -$38.17 M(+36.0%) | -$98.35 M(+21.3%) |
| Dec 2007 | -$81.09 M(+41.4%) | -$28.06 M(+82.6%) | -$81.09 M(+52.9%) |
| Sept 2007 | - | -$15.37 M(-8.2%) | -$53.03 M(+40.8%) |
| June 2007 | - | -$16.75 M(-19.9%) | -$37.66 M(+80.1%) |
| Mar 2007 | - | -$20.91 M | -$20.91 M |
| Dec 2006 | -$57.35 M(+9.9%) | - | - |
| Dec 2005 | -$52.16 M | - | - |
FAQ
- What is Jazz Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals annual CFO year-on-year change?
- What is Jazz Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals quarterly CFO year-on-year change?
- What is Jazz Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals TTM CFO year-on-year change?
What is Jazz Pharmaceuticals annual cash flow from operations?
The current annual CFO of JAZZ is $1.09 B
What is the all time high annual CFO for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high annual cash flow from operations is $1.27 B
What is Jazz Pharmaceuticals annual CFO year-on-year change?
Over the past year, JAZZ annual cash flow from operations has changed by -$179.97 M (-14.15%)
What is Jazz Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of JAZZ is $398.75 M
What is the all time high quarterly CFO for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high quarterly cash flow from operations is $417.99 M
What is Jazz Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, JAZZ quarterly cash flow from operations has changed by +$91.55 M (+29.80%)
What is Jazz Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of JAZZ is $1.16 B
What is the all time high TTM CFO for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high TTM cash flow from operations is $1.38 B
What is Jazz Pharmaceuticals TTM CFO year-on-year change?
Over the past year, JAZZ TTM cash flow from operations has changed by -$101.97 M (-8.05%)